Kids with IBD (inflammatory bowel disease) often struggle with tiredness and difficulty doing everyday activities, which can make life harder, but there aren't good tools to measure these problems in children. This study aims to create special tools to measure fatigue and disability in kids aged 2-18. Researchers will talk to kids and their parents to find out what issues matter most and use this information, along with medical records, to design the tools. The goal is to help doctors track these problems better and improve care for children with IBD. This study is being done in collaboration with the Shaare Zedek Medical Center. Participants will be compensated for their time and effort, upon completion of the interview.

The goals of this research study are to learn more about acute recurrent and chronic pancreatitis in order to better understand the disease in the hopes of enhancing future treatment options. If you and your child agree to participate you will each be asked to: meet with the study team at your annual check-up, complete questionnaires about medical history, family history, and quality of life, agree to a one-time blood or saliva sample collection. All participants will be compensated for their time and effort. If you would be interested in participating, please contact study coordinator Lucia Sanchez by phone at 267-426-8411, or email at sanchezlc@email.chop.edu.

This study was designed to measure components or metabolites of PEG 3350 in blood and urine from children who were already taking PEG 3350 and to compare these levels to measurements of the same molecules from a group of children who were not taking PEG 3350. PEG 3350 was not prescribed as part of this study. Participants completed questionnaires and provided access to their medical records.Enrollment for this study has been completed. Laboratory analysis of specimens and data analysis are being conducted. This work will be submitted for publication once all analyses have been completed. When available, study results will be accessible on https://classic.clinicaltrials.gov/ct2/show/NCT05424757.

The RE-EEN Smoothie Study is recruiting patients newly diagnosed with Crohn's Disease who are interested in using diet to help achieve disease remission. The purpose of the study is to evaluate the use of a whole-food based smoothie as Exclusive Enteral Nutrition for Crohn's Disease. In this study, participants will be randomly assigned to receive either a whole-food based smoothie, or formula as Exclusive Enteral Nutrition (EEN) therapy for Crohn's Disease. Participants will work closely with the study dietician to ensure that all of their nutritional needs are met during their participation in the study.

The Childrens Hospital of Philadelphia is seekinghealthy adolescents between the ages of 12-13, who are currently in the 7^thgrade,to participate in the Sleep and Growth Study 2. The purpose of this research is to learn more about the changes in sleep and body size in adolescents as they transition from middle to high school. Participants will be asked to visit CHOP so that we can measure their bone density. Following this visit, participants will wear a sleep tracker over a 2-week period and speak to a team member by phone on three occasions about the types of food eaten in the previous 24 hours. If you and your child agree to participate, the study will involve 3 visits over approximately 2 years. All participants are compensated for their time and effort.For more information and study details, please call 215-590-2383, ext. 1, or emails_grow@chop.edu.

The goal of this study is to find out if we can develop a digital health approach that can increase sleep duration and improve growth outcomes in children.

The purpose of this research study is to help us understand how well tofacitinib works as a treatment for ulcerative colitis or indeterminate colitis in pediatric patients. We are looking to enroll, males or females ages 6 to 21 years old with a diagnosis of ulcerative colitis or indeterminate colitis who have started tofacitinib therapy prescribed by their primary gastroenterologist within the past 2 weeks or will be starting tofafacitinib within 1 month.

Use of elexacaftor-texacaftor-ivacaftor ("ETI"), also known as Trikafta, is associated with weight gain in most people with cystic fibrosis (CF) who take this medication. However, some people gain more or less weight than is expected, and this can be either beneficial or problematic based on the individual's starting weight. The goal of this study is to compare factors between children and young adults with CF who have either had robust or minimal weight gain after one year of treatment with ETI.This observational study requires one study visit to CHOP that will last approximately 6 hours.